Selected research
Market Structure
Global Celiac Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Celiac Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Celiac Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Celiac Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Celiac Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Celiac Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Celiac Drugs include Johnson & Johnson, Novartis, Merck, Biogen, Bayer, Amgen, LFB Group, Kedrion Biopharma and Innovate Biopharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Celiac Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Celiac Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Celiac Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Celiac Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Celiac Drugs Segment by Company
Johnson & Johnson
Novartis
Merck
Biogen
Bayer
Amgen
LFB Group
Kedrion Biopharma
Innovate Biopharmaceuticals
ImmusanT
Immunomedics
ImmunogenX
F Hoffmann-La Roche
Celimmune
Celgene
Bristol-Myers Squibb
Biotest
BioLineRx
Anthera Pharmaceuticals
ADMA Biologics
Celiac Drugs Segment by Type
First Line Of Treatment
Second Line Of Treatment
Celiac Drugs Segment by Application
Women
Men
Children
Celiac Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Celiac Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Celiac Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Celiac Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Celiac Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Celiac Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Celiac Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Celiac Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- First Line Of Treatment
- Second Line Of Treatment
Applications
- Women
- Men
- Children
Companies covered
- Johnson & Johnson
- Novartis
- Merck
- Biogen
- Bayer
- Amgen
- LFB Group
- Kedrion Biopharma
- Innovate Biopharmaceuticals
- ImmusanT
- Immunomedics
- ImmunogenX
- F Hoffmann-La Roche
- Celimmune
- Celgene
- Bristol-Myers Squibb
- Biotest
- BioLineRx
- Anthera Pharmaceuticals
- ADMA Biologics
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Celiac Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Celiac Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Celiac Drugs Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Celiac Drugs Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Celiac Drugs Market Dynamics
- 2.1 Celiac Drugs Industry Trends
- 2.2 Celiac Drugs Industry Drivers
- 2.3 Celiac Drugs Industry Opportunities and Challenges
- 2.4 Celiac Drugs Industry Restraints
3 Celiac Drugs Market by Manufacturers
- 3.1 Global Celiac Drugs Revenue by Manufacturers (2021-2026)
- 3.2 Global Celiac Drugs Sales by Manufacturers (2021-2026)
- 3.3 Global Celiac Drugs Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Celiac Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Celiac Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Celiac Drugs Manufacturers, Product Type & Application
- 3.7 Global Celiac Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Celiac Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Celiac Drugs Players Market Share by Revenue in 2025
- 3.8.3 2025 Celiac Drugs Tier 1, Tier 2, and Tier 3
4 Celiac Drugs Market by Type
- 4.1 Celiac Drugs Type Introduction
- 4.1.1 First Line Of Treatment
- 4.1.2 Second Line Of Treatment
- 4.2 Global Celiac Drugs Sales by Type
- 4.2.1 Global Celiac Drugs Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Celiac Drugs Sales by Type (2021-2032)
- 4.2.3 Global Celiac Drugs Sales Market Share by Type (2021-2032)
- 4.3 Global Celiac Drugs Revenue by Type
- 4.3.1 Global Celiac Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Celiac Drugs Revenue by Type (2021-2032)
- 4.3.3 Global Celiac Drugs Revenue Market Share by Type (2021-2032)
5 Celiac Drugs Market by Application
- 5.1 Celiac Drugs Application Introduction
- 5.1.1 Women
- 5.1.2 Men
- 5.1.3 Children
- 5.2 Global Celiac Drugs Sales by Application
- 5.2.1 Global Celiac Drugs Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Celiac Drugs Sales by Application (2021-2032)
- 5.2.3 Global Celiac Drugs Sales Market Share by Application (2021-2032)
- 5.3 Global Celiac Drugs Revenue by Application
- 5.3.1 Global Celiac Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Celiac Drugs Revenue by Application (2021-2032)
- 5.3.3 Global Celiac Drugs Revenue Market Share by Application (2021-2032)
6 Global Celiac Drugs Sales by Region
- 6.1 Global Celiac Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Celiac Drugs Sales by Region (2021-2032)
- 6.2.1 Global Celiac Drugs Sales by Region (2021-2026)
- 6.2.2 Global Celiac Drugs Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Celiac Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Celiac Drugs Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Celiac Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Celiac Drugs Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Celiac Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Celiac Drugs Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Celiac Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Celiac Drugs Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Celiac Drugs Revenue by Region
- 7.1 Global Celiac Drugs Revenue by Region
- 7.1.1 Global Celiac Drugs Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Celiac Drugs Revenue by Region (2021-2026)
- 7.1.3 Global Celiac Drugs Revenue by Region (2027-2032)
- 7.1.4 Global Celiac Drugs Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Celiac Drugs Revenue (2021-2032)
- 7.2.2 North America Celiac Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Celiac Drugs Revenue (2021-2032)
- 7.3.2 Europe Celiac Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Celiac Drugs Revenue (2021-2032)
- 7.4.2 Asia-Pacific Celiac Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Celiac Drugs Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Celiac Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Johnson & Johnson
- 8.1.1 Johnson & Johnson Company Information
- 8.1.2 Johnson & Johnson Business Overview
- 8.1.3 Johnson & Johnson Celiac Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Johnson & Johnson Celiac Drugs Product Portfolio
- 8.1.5 Johnson & Johnson Recent Developments
- 8.2 Novartis
- 8.2.1 Novartis Company Information
- 8.2.2 Novartis Business Overview
- 8.2.3 Novartis Celiac Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Novartis Celiac Drugs Product Portfolio
- 8.2.5 Novartis Recent Developments
- 8.3 Merck
- 8.3.1 Merck Company Information
- 8.3.2 Merck Business Overview
- 8.3.3 Merck Celiac Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Merck Celiac Drugs Product Portfolio
- 8.3.5 Merck Recent Developments
- 8.4 Biogen
- 8.4.1 Biogen Company Information
- 8.4.2 Biogen Business Overview
- 8.4.3 Biogen Celiac Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Biogen Celiac Drugs Product Portfolio
- 8.4.5 Biogen Recent Developments
- 8.5 Bayer
- 8.5.1 Bayer Company Information
- 8.5.2 Bayer Business Overview
- 8.5.3 Bayer Celiac Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Bayer Celiac Drugs Product Portfolio
- 8.5.5 Bayer Recent Developments
- 8.6 Amgen
- 8.6.1 Amgen Company Information
- 8.6.2 Amgen Business Overview
- 8.6.3 Amgen Celiac Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Amgen Celiac Drugs Product Portfolio
- 8.6.5 Amgen Recent Developments
- 8.7 LFB Group
- 8.7.1 LFB Group Company Information
- 8.7.2 LFB Group Business Overview
- 8.7.3 LFB Group Celiac Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 LFB Group Celiac Drugs Product Portfolio
- 8.7.5 LFB Group Recent Developments
- 8.8 Kedrion Biopharma
- 8.8.1 Kedrion Biopharma Company Information
- 8.8.2 Kedrion Biopharma Business Overview
- 8.8.3 Kedrion Biopharma Celiac Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Kedrion Biopharma Celiac Drugs Product Portfolio
- 8.8.5 Kedrion Biopharma Recent Developments
- 8.9 Innovate Biopharmaceuticals
- 8.9.1 Innovate Biopharmaceuticals Company Information
- 8.9.2 Innovate Biopharmaceuticals Business Overview
- 8.9.3 Innovate Biopharmaceuticals Celiac Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Innovate Biopharmaceuticals Celiac Drugs Product Portfolio
- 8.9.5 Innovate Biopharmaceuticals Recent Developments
- 8.10 ImmusanT
- 8.10.1 ImmusanT Company Information
- 8.10.2 ImmusanT Business Overview
- 8.10.3 ImmusanT Celiac Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 ImmusanT Celiac Drugs Product Portfolio
- 8.10.5 ImmusanT Recent Developments
- 8.11 Immunomedics
- 8.11.1 Immunomedics Company Information
- 8.11.2 Immunomedics Business Overview
- 8.11.3 Immunomedics Celiac Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Immunomedics Celiac Drugs Product Portfolio
- 8.11.5 Immunomedics Recent Developments
- 8.12 ImmunogenX
- 8.12.1 ImmunogenX Company Information
- 8.12.2 ImmunogenX Business Overview
- 8.12.3 ImmunogenX Celiac Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 ImmunogenX Celiac Drugs Product Portfolio
- 8.12.5 ImmunogenX Recent Developments
- 8.13 F Hoffmann-La Roche
- 8.13.1 F Hoffmann-La Roche Company Information
- 8.13.2 F Hoffmann-La Roche Business Overview
- 8.13.3 F Hoffmann-La Roche Celiac Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 F Hoffmann-La Roche Celiac Drugs Product Portfolio
- 8.13.5 F Hoffmann-La Roche Recent Developments
- 8.14 Celimmune
- 8.14.1 Celimmune Company Information
- 8.14.2 Celimmune Business Overview
- 8.14.3 Celimmune Celiac Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.14.4 Celimmune Celiac Drugs Product Portfolio
- 8.14.5 Celimmune Recent Developments
- 8.15 Celgene
- 8.15.1 Celgene Company Information
- 8.15.2 Celgene Business Overview
- 8.15.3 Celgene Celiac Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.15.4 Celgene Celiac Drugs Product Portfolio
- 8.15.5 Celgene Recent Developments
- 8.16 Bristol-Myers Squibb
- 8.16.1 Bristol-Myers Squibb Company Information
- 8.16.2 Bristol-Myers Squibb Business Overview
- 8.16.3 Bristol-Myers Squibb Celiac Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.16.4 Bristol-Myers Squibb Celiac Drugs Product Portfolio
- 8.16.5 Bristol-Myers Squibb Recent Developments
- 8.17 Biotest
- 8.17.1 Biotest Company Information
- 8.17.2 Biotest Business Overview
- 8.17.3 Biotest Celiac Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.17.4 Biotest Celiac Drugs Product Portfolio
- 8.17.5 Biotest Recent Developments
- 8.18 BioLineRx
- 8.18.1 BioLineRx Company Information
- 8.18.2 BioLineRx Business Overview
- 8.18.3 BioLineRx Celiac Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.18.4 BioLineRx Celiac Drugs Product Portfolio
- 8.18.5 BioLineRx Recent Developments
- 8.19 Anthera Pharmaceuticals
- 8.19.1 Anthera Pharmaceuticals Company Information
- 8.19.2 Anthera Pharmaceuticals Business Overview
- 8.19.3 Anthera Pharmaceuticals Celiac Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.19.4 Anthera Pharmaceuticals Celiac Drugs Product Portfolio
- 8.19.5 Anthera Pharmaceuticals Recent Developments
- 8.20 ADMA Biologics
- 8.20.1 ADMA Biologics Company Information
- 8.20.2 ADMA Biologics Business Overview
- 8.20.3 ADMA Biologics Celiac Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.20.4 ADMA Biologics Celiac Drugs Product Portfolio
- 8.20.5 ADMA Biologics Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Celiac Drugs Value Chain Analysis
- 9.1.1 Celiac Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Celiac Drugs Production Mode & Process
- 9.2 Celiac Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Celiac Drugs Distributors
- 9.2.3 Celiac Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst